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ABSTRACT
Point-of-care (POC) tests for inﬂuenza facilitate clinical case management, and might also be helpful in
the care of travellers who are at special risk for inﬂuenza infection. To evaluate inﬂuenza POC testing in
travellers, a new assay, the ImmunoCard STAT! Flu A and B, was used to investigate travellers
presenting with inﬂuenza-like symptoms. Inﬂuenza virus infection was diagnosed in 27 (13%) of 203
patients by inﬂuenza virus-speciﬁc PCR and viral culture. The POC test had sensitivity and speciﬁcity
values of 64% and 99% for inﬂuenza A, and 67% and 100% for inﬂuenza B, respectively. Combined
sensitivity and speciﬁcity were 67% and 99%, respectively, yielding positive and negative predictive
values of 95%, and positive and negative likelihood ratios of 117 and 0.34, respectively. The convenient
application, excellent speciﬁcity and high positive likelihood ratio of the POC test allowed rapid
identiﬁcation of inﬂuenza cases. However, negative test results might require conﬁrmation by other
methods because of limitations in sensitivity. Overall, inﬂuenza POC testing appeared to be a useful tool
for the management of travellers with inﬂuenza-like symptoms.
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INTRODUCTION
Respiratory infections occur in c. 6–58% of all
travellers [1], with ‡5% of these infections being
caused by inﬂuenza viruses [2]. Consequently,
inﬂuenza might be the most frequent vaccine-
preventable infection among travellers [3]. Rea-
sons for the high incidence of infection might be
overcrowding during transportation or in accom-
modation [2], climatic conditions favourable to
viruses during air travel [4], and the year-round
presence of inﬂuenza viruses in tropical areas
(http://www.who.int/mediacentre/factsheets/
fs211/en). In addition to the risk of infection for
individuals, the dissemination of inﬂuenza and
other respiratory infections via travellers is an
emerging concern [5]. Appropriate management
of respiratory infections, e.g., inﬂuenza or SARS,
depends on rapid and reliable diagnostic tests
that can assist patient care by enabling early
antiviral treatment, prophylaxis of contacts, and
epidemiological investigations [6] (http://www.
who.int/csr/disease/avian_inﬂuenza/guidelines/
rapid_testing/en).
Several point-of-care (POC) inﬂuenza tests allow
a more rapid and economical diagnosis than
conventional laboratory methods, e.g., viral cul-
ture, PCR or direct immunoﬂuorescence tests [7].
However, data concerning the performance of
these POC tests are limited, and often derive from
non-peer-reviewed manufacturers’ studies [8].
The WHO encourages POC testing in travellers
and lists 19 available POC assays (http://www.
who.int/csr/disease/avian_inﬂuenza/guidelines/
rapid_testing/en). However, studies concerning
the performance characteristics of POC tests for
inﬂuenza in travellers have not been performed
previously. Therefore, the aim of the present study
was to evaluate a new POC assay in a popula-
tion of travellers presenting with inﬂuenza-like
symptoms.
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PATIENTS AND METHODS
Between February 2005 and November 2006, individuals who
attended the outpatient department of the Institute of Tropical
Medicine and International Health, Berlin, Germany with
inﬂuenza-like symptoms were tested for inﬂuenza virus.
Depending on the travel history and clinical presentation,
diagnostic tests for other infections, e.g., malaria and dengue
fever, were also conducted. For the diagnosis of inﬂuenza, two
nasal swabs were taken on dry rayon swabs (Copan Diagnos-
tics Inc., Corona, CA, USA). One specimen from each patient
was tested immediately with the ImmunoCard STAT! Flu A
and B (Meridian Bioscience, Cincinnati, OH, USA) POC test
according to the manufacturer’s instructions. This test, which
works as a lateral ﬂow immunochromatographic assay, based
on monoclonal antibodies speciﬁc for inﬂuenza nucleoprotein,
is able to differentiate between inﬂuenza A and B infections.
After the POC test had been performed, the ﬁrst swab was
kept at )20C as a back-up sample. The second specimen from
each patient was sent to the German National Reference Center
for Inﬂuenza, Berlin. To avoid desiccation during transport,
0.5 mL of sterile saline 0.9% w ⁄v (Braun AG, Melsungen,
Germany) was added. The samples were transported on the
same day they were taken, or if transport was delayed, kept
frozen at )20C.
At the German Inﬂuenza Reference Center, all samples
were immediately tested for inﬂuenza virus by PCR and
viral culture as described elsewhere [9]. Changes in the
standard protocol included the substitution of two primers
(HA3-115, HA3-375) for detection of the haemagglutinin
gene of inﬂuenza A ⁄H3 by primers H3P-162 (5¢-TCCT-
CATCAGATCCTTGATG) and H3P-291 (5¢-ACAGTTGCTGT-
AGGCTTTGC), and of the primers for detection of inﬂuenza
B viruses by primers BMP-1 (5¢-GAGACACAATTGCCT-
ACCTGC), BMP-2 (5¢-CCACCGAACCAACAGTGTAAT)
and probe BMP-72 FAM (5¢-AGATGGAGAAGGCAAAGC-
AGAACTAGC). In brief, following initial extraction of RNA
with a QIAamp Viral RNA Kit (Qiagen, Hilden, Germany),
material from the swabs was analysed using TaqMan PCR
with the above primers and probe. Virus culture was
performed on Madin–Darby canine kidney cells, and positive
cultures were analysed further using the classic haemagglu-
tination inhibition procedures [10].
For patients positive by the POC test and negative by PCR
and virus culture, the respective back-up samples were
retested to conﬁrm the results. Samples were considered to
be positive if inﬂuenza A or B virus was detected by inﬂuenza-
speciﬁc PCR and ⁄ or virus culture. Travel-associated inﬂuenza
was assumed if patients reported the onset of symptoms
within 4 days of return from travel, and if the period between
symptom onset and sampling was <7 days.
Data were analysed using SAS v.8.01 software (SAS
Institute Inc., Cary, NC, USA).
RESULTS
During the study period, samples from 203
individuals with a recent history of international
travel were examined. All subjects reported inﬂu-
enza-like symptoms, including headache ⁄myalgia
(91%), fever (90%) and cough (69%). The subjects
had an almost even gender distribution (51%
male, 49% female) and had a median age of
37 years (range 4–80 years). Two subjects were
aged <8 years. Inﬂuenza infection was diagnosed
in a total of 27 (13.3%) individuals by inﬂuenza-
speciﬁc PCR or virus culture. Inﬂuenza A and B
virus were identiﬁed in 22 and six cases, respec-
tively, with one double infection. All inﬂuenza A
virus isolates, except two H1N1 strains, were
subtyped as H3N2. Fourteen inﬂuenza-positive
subjects did not fulﬁl the criteria for travel-
associated inﬂuenza; the other 13 subjects
acquired inﬂuenza infections during travel to
Asia (84%), Africa (8%) and Latin America
(8%).
The ImmunoCard STAT! Flu A and B POC test
results were available in 20–25 min and are
summarised in Table 1. Among the 22 subjects
with inﬂuenza A virus, specimens from 14 indi-
viduals displayed a positive inﬂuenza A virus
band, while eight subjects were not detected by
the POC assay. For ten subjects, only a weak or
very weak inﬂuenza band was visible. Nine of
these individuals were conﬁrmed as positive by
PCR or culture. One sample with a weak inﬂu-
enza A virus band was repeatedly negative by
PCR and culture. Of the six individuals with
inﬂuenza B virus, four were identiﬁed correctly
and two were missed by the POC test. The subject
with an inﬂuenza A and B double infection
yielded only an inﬂuenza B virus band. Overall,
the combined sensitivity and speciﬁcity of the
POC test were 67% and 99%, respectively, result-
ing in positive and negative predictive values of
95%, and positive and negative likelihood ratios
of 117 and 0.34, respectively. The ten cases of
inﬂuenza not detected by POC testing did not
differ from the other cases in terms of their
clinical presentation or the period between symp-
tom onset and diagnosis.
DISCUSSION
Rapid detection of inﬂuenza virus by POC assays
facilitates clinical management and treatment
decisions for individuals with possible inﬂuenza.
However, the performance and impact of this
approach depends on the epidemiological situ-
ation for a particular population [11] (http://www.
who.int/csr/disease/avian_inﬂuenza/guidelines/
rapid_testing/en). In terms of inﬂuenza, travellers
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represent a complex population, since: (a) they
might be exposed continuously in the tropics, or
during a reversed season in the southern hemi-
sphere; and (b) travelling involves close contact
with individuals from different geographical
areas under conditions that are favourable for
the transmission of respiratory infections [12].
Although travellers are at increased risk, epide-
miological data concerning inﬂuenza virus in
travellers are scarce. A retrospective study repor-
ted a prevalence of 5.6% in travellers with
respiratory symptoms [2], while a serological
evaluation detected inﬂuenza seroconversion in
2.8% of all travellers, and in 12.8% of febrile
travellers [13]. In the present study, inﬂuenza
infection was found in 13.3% of the population of
outpatients with inﬂuenza-like symptoms and a
history of travel. If the analysis was limited to
individuals with possible travel-acquired inﬂu-
enza, inﬂuenza virus was detected in 13 (15.5%)
of 84 subjects. The different rates of inﬂuenza
probably reﬂect different study populations and
denominators, and therefore require further veri-
ﬁcation in prospective studies.
The WHO encourages the use of POC testing in
travellers, since it allows rapid decisions to be
made concerning the management of patients and
contacts (http://www.who.int/csr/disease/avian_
inﬂuenza/guidelines/rapid_testing/en). However,
this recommendation has not yet been evaluated
in clinical practice. The present study provides
the ﬁrst data concerning systematic POC testing
in travellers using a newly developed POC test,
the ImmunoCard STAT! Flu A and B assay.
A limitation of the study was the bias towards
mild or moderate infections, since only outpa-
tients were tested. In addition, the requirement
for two nasal swabs might have caused discord-
ant results because of an uneven virus distribu-
tion. However, it was decided to use this easy and
relatively non-invasive sampling method because
other techniques, e.g., nasopharyngeal aspirates,
which might have resulted in specimens of higher
quality, were impractical and almost impossible
to use among adult outpatients.
The ImmunoCard STAT! Flu A and B test was
easy and convenient to perform. Rapid results
allowed prompt management and notiﬁcation of
cases. Faint or very faint test results, observed for
ten subjects, were conﬁrmed in all except one
case, which highlighted the fact that even very
faint bands must be regarded as positive. The
interpretation of very weak results could be
problematic in inexperienced hands and should
be addressed by the manufacturer to avoid false-
negative results. The assay reached sensitivity
and speciﬁcity values comparable to those in
previous evaluations of the same [14] or similar
POC tests [15–18].
In general, inﬂuenza POC tests display high
speciﬁcity rates, but moderate-to-low sensitivi-
ties, ranging from 29% to >90%, with a median
sensitivity of c. 70% (http://www.who.int/csr/
disease/avian_inﬂuenza/guidelines/rapid_testing/
en), although lower sensitivities have been
reported for inﬂuenza B tests [19]. Varying
sensitivities might be test-speciﬁc, but could also
reﬂect different study populations, sampling
techniques and comparative assays. For example,
POC test sensitivities in studies of children are
often higher, which might be explained by
increased shedding of virus in young patients
[20,21]. In addition, test performance is better in
high-prevalence months and in patients with
severe infections [22]. Nasopharyngeal aspirates
or washings have been shown to be superior to
nasal or throat swabs [17,18]. Considering that
97% of the present study population consisted of
adult outpatients, and that nasal swabs were
used, it is likely that the sensitivity of the
ImmunoCard STAT! Flu A and B assay might
be higher with children and hospitalised
patients, or if more invasive sampling was
performed.
Table 1. Diagnostic characteristics of the ImmunoCard STAT! Flu A and B point-of-care test
PCR ⁄ culture
Inﬂuenza A POC test Inﬂuenza B POC test Inﬂuenza A or B POC test
Specimen
(n)
Sensitivity Speciﬁcity
Specimen
(n)
Sensitivity Speciﬁcity
Specimen
(n)
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)+ve –ve +ve –ve +ve –ve
Positive 14 8 64% 99% 4 2 67% 100% 18 9 67% 99% 95% 95%
Negative 1 180 0 197 1 175 (49–84) (98–100) (85–100) (85–100)
PPV, positive predictive value; NPV, negative predictive value.
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A high positive and negative predictive value
of 95% was achieved with the present patient
group. The excellent speciﬁcity and high positive
likelihood ratio of the test allowed prompt and
reliable diagnosis of positive cases. This not only
facilitates the clinical management of inﬂuenza
infection, but also helps to minimise unneces-
sary tests for other febrile tropical diseases, e.g.,
malaria or dengue fever, which often require
repeated examinations. The cost-effectiveness of
diagnostic strategies that include inﬂuenza POC
tests has been demonstrated previously in other
patient groups, e.g., children in emer-
gency departments, where a reduction in both
diagnostic tests and the use of antibiotics was
observed [23–26].
The test sensitivity of 67% and negative likeli-
hood ratio of 0.34 among the present population
suggest that, in cases of high clinical suspicion,
negative results need further conﬁrmation by
additional methods such as PCR or culture. In
addition, since POC assays miss a substantial
proportion of inﬂuenza cases, their general use as
a surveillance or screening tool in patients with
respiratory symptoms may pose a risk [6], but
inﬂuenza POC tests might be able to rapidly
identify human cases of avian inﬂuenza, e.g., in
travellers returning from Asia [27]. However, to
exclude or monitor human cases with new and
more virulent inﬂuenza strains, more sensitive
techniques such as real-time PCR are required. To
generate more valid test results, POC assays with
improved sensitivity should be developed. In
addition, test markers indicating the quality of the
tested respiratory specimen would be helpful in
supporting negative test results. Finally, inclusion
of other important respiratory pathogens would
further improve the value of a POC assay in the
management of patients with imported respirat-
ory infections.
In summary, the acceptable performance char-
acteristics of the inﬂuenza POC assay evaluated in
this study indicate that it is a useful tool for the
diagnosis of travellers with inﬂuenza-like or
respiratory symptoms. At present, POC tests are
the only inexpensive option available for timely
diagnosis of inﬂuenza, which is essential for
further decisions concerning the use of antiviral
drugs and isolation procedures for patients and
their contacts. Rapid conﬁrmation of inﬂuenza
infections in travellers also augments the exclu-
sion of other imported infections that require
immediate treatment or isolation measures, e.g.,
malaria or SARS.
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